



From the desk of  
**Hannah Deresiewicz**

Happy 2025!

The new year is off to a strong start and I am delighted to relaunch the Precision AQ (formerly Stern IR) monthly newsletter!

Nearly 18 months ago, I stepped into the leadership role at Precision AQ under the tutelage of our founder, Lilian Stern, with whom I had worked for nearly a dozen years. I want to take this opportunity to acknowledge Lilian's incredible leadership and dedication, noting her retirement marks the end of a remarkable chapter for our company. Her vision and commitment laid a strong foundation for us to build upon and I am both honored and excited to lead Precision AQ's investor relations, public relations and external communications team into its next phase of growth and innovation. Together, we will continue to uphold the values and standards Lilian set that have made Precision AQ a leader in life science investor relations.

We issue this month's newsletter just weeks after our return from San Francisco, where the Precision team spent a (Busy! Long! Exhausting! Fun!) week connecting live with our clients and the Wall St. community.

JP Morgan has always been one of my favorite times of the year! I love the energy, the optimism for the year ahead, and the opportunity to connect with so many industry friends and colleagues. More than anything – regardless of how the markets perform or what headlines focus on – JP Morgan provides an incredible opportunity to reflect on the power of our industry to bring together passionate, brilliant leaders; to transform science into breakthrough treatments; and to deliver life-changing medicines to patients. Importantly, it is the best reminder of our good fortune to partner with companies at the very forefront of those innovations.

This year was no exception. As you'll read below, Precision AQ hosted ~70 clients, scheduled more than 2300 meetings, and supported our client companies in announcing strong commercial performances, promising clinical data, major M&A and other important corporate updates.

This was a Herculean effort, and I am so grateful to my colleagues who spent months developing press releases and presentations, building schedules, and coordinating logistics to ensure a smooth and productive event.

Our team returned to New York invigorated and excited for the year ahead, and we look forward to your partnership as we move into 2025 and beyond!

Going forward, our newsletter will be a forum for the Precision AQ team to share our thinking on the biotech industry and markets more broadly, to spotlight several of our public and private clients, and to introduce you to our incredible colleagues from across Precision – a global team of 3,500 experts, who provide R&D, clinical and commercialization services to life science organizations across the drug development continuum. We hope you enjoy and, of course, welcome your thoughts on any topics or content you'd like to see from us in future editions.

All the best in 2025!  
Hannah

## Corporate Access Event

## JP Morgan 2025



**~70**  
CLIENTS

**2,300+**  
MEETINGS

**450+**  
PARTY ATTENDEES

**100+**  
GALLONS OF COFFEE

**100+**  
LBS. OF CANDY

**0**  
UMBRELLAS

- Hosted nearly **70 clients** and over **2,300 meetings** in our suites and other locations across San Francisco
- **Recorded 14** Access to the Best and Brightest videos for clients in our brand-new production suite
- **Ran 8 sell-side events** over the course of 3 days at The Marker
- Held our best-ever cocktail party with **450+** attendees

## Client Fundraises in 2024

**4.95B**  
DOLLARS RAISED

**17**  
FOLLOW-ON OFFERINGS

**5**  
VC DEALS

**3**  
PIPEs

**2**  
PRIVATE PLACEMENTS/  
REGISTERED DIRECTS

**1**  
IPO

## Client Shoutout



**Congratulation** to Precision AQ client, **Scorpion Therapeutics**, for having its **P13K $\alpha$  inhibitor** program acquired by **Eli Lilly** for up to **\$2.5 billion** in cash.

**STX-478**, Scorpion's potentially best-in-class, mutant-selective PI3K $\alpha$  inhibitor, is currently being evaluated in Phase 1/2 clinical trials for breast cancer and other advanced solid tumors.

## Street Moves People on the Move

### Buyside

**Deanna Belsky** formerly at Cormorant Asset Management, LP, has changed firms to Balyasny Asset Management

**Katerina Popova** formerly at Aquilio Capital Management, has changed firms to KCap Biotechnology Fund

**David Ketteridge** has left Temasek

**Petter Johnsen** formerly at Norges Bank Investment Management, has changed firms to ICP Asset Management

**Cynthia Chen** formerly at T. Rowe Price Investment Management, has changed firms to StemPoint Capital

**Morgan Haller** formerly at Kempen, has joined Forbion

### Research

**Lousie Chen** formerly at Cantor Fitzgerald, has changed firms to Scotiabank

**William Maughan**, formerly at Canaccord Genuity Securities LLC, has changed firms to Clear Street LLC

**Guofang Li** formerly an analyst at Leerink Partners LLC, has changed firms to Chardan Capital Markets

### Banking

**Phillipe Gallone** formerly at Moelis, has changed firms to Goldman Sachs

**Terence Tan** formerly at Cantor Fitzgerald, has moved to William Blair's banking team

**Jami Rubin** formerly at ARCH Ventures, has joined Guggenheim's banking team

**Charles Wang** reviously at Mizuho, has joined the banking team at Leerink Partners

**James Burnes** formerly at Cantor Fitzgerald, has changed firms to Moelis

**Nishant Saxena** has left his banking role at Evercore for a CFO role at Jeune Aesthetics

**Michael Ryal** has left Dawson James Securities

## Access to the Best & Brightest



**Shehnaaz Suliman, M.D., M.B.A., M.Phil.**

Chief Executive Officer of ReCode Therapeutics, sat down with Precision AQ EVP & Managing Director, Hannah Deresiewicz, at the Precision AQ Corporate Access to the Best in San Francisco last month to discuss ReCode's development of precision genetic medicines.

## PR Brief The Precision AQ PR Way

## BREAKING NEWS

In a recently published article, Endpoints sat down with the Orna Therapeutics' team to discuss the recent partnership announcement with Vertex and what it means for the biotech's next generation of gene editing treatments.

<https://endpts.com/vertex-signs-in-vivo-gene-editing-delivery-pact-for-sickle-cell-and-thalassemia-with-orna-therapeutics/>



To learn more about how **Precision AQ** can spotlight and elevate your company through strategic communications and public relations, please contact [Ethan.Metelenis@precisionaq.com](mailto:Ethan.Metelenis@precisionaq.com)

*“The partnership announcement comes just over a year after Vertex received the first approval for a gene-edited therapy for sickle cell disease and thalassemia known as Casgevy. Vertex paid Orna \$65 million, including an undisclosed amount in a convertible note. All in all, Orna could receive up to \$635 million in milestones for the sickle cell and thalassemia programs. It could receive another \$365 million per target related to up to 10 additional programs in other indications if Vertex opts in. Orna's also eligible for tiered royalties on a potential product from this deal.”*

## Investor Conference List February 2025

### Healthcare Investor Conferences

Dates	March 2025 Events	Locations
3/2-3/5	Raymond James: Annual Institutional Investors Conference	Orlando
3/3-3/4	Morgan Stanley European Healthcare Conference	London
3/3-3/5	Cowen 45th Annual Healthcare Conference	Boston
3/4-3/5	UBS European Healthcare Conference	London
3/10	Jefferies Value-Based Healthcare Summit	Miami
3/10	Canaccord Genuity Musculoskeletal Conference	San Diego
3/10	Wedbush Cardiometabolic Conference	Miami
3/10-3/12	Leerink Partners Global Biopharma Conference	Miami
3/10-3/12	Jefferies Value-Based Healthcare Summit	Miami
3/11-3/13	Barclays Global Healthcare Conference	Miami
3/12-3/14	Goldman Sachs Healthcare Senior Executives Ski Outing 2025	Park City, Utah
3/16-3/18	37th Annual Roth Conference	Dana Point, CA
3/18-3/19	Stifel 2025 CNS Day	Virtual
3/18-3/19	KeyBanc Capital Markets Life Sciences and MedTech Investor Forum	Virtual
3/18-3/21	TD Cowen's 23rd Annual Life Sciences Winter Meeting & Ski Trip	Vail, Colorado
3/19-3/20	Sidoti Small Cap Conference	Virtual
3/20-3/21	RBC Capital Markets Virtual Ophthalmology Conference	Virtual
3/25	Jefferies' 5th Annual Pan-European Mid-Cap Conference	London
3/25-3/26	Goldman Sachs Healthcare Innovation Forum	London
3/27	H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference	Virtual